Milestone Scientific Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLSS research report →
Range $1 – $1
Price Chart
About the company
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets.
- CEO
- Eric C. Hines
- IPO
- 1995
- Employees
- 15
- HQ
- Roseland, NJ, US
Get TickerSpark's AI analysis on MLSS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.75M
- P/E
- -5.82
- PEG
- -0.07
- P/S
- 2.37
- P/B
- 6.23
- EV/EBITDA
- -5.85
- Div Yield
- 0.00%
- Gross Margin
- 70.50%
- Op Margin
- -40.04%
- Net Margin
- -40.27%
- ROE
- -122.29%
- ROIC
- -98.56%
Latest fiscal year · YoY change
- Revenue
- $8.97M+4.0%
- Gross Profit
- $6.33M-1.6%
- Op Income
- $-5,696,617
- Net Income
- $-5,722,216-21.4%
- EPS
- $-0.07-18.4%
- OCF Growth
- +0.1%
- FCF Growth
- -0.1%
- 52W High
- $0.58
- 52W Low
- $0.22
- 50D MA
- $0.35
- 200D MA
- $0.36
- Beta
- 1.16
- RSI (14)
- 30
- Avg Volume
- 100.22K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Milestone reported a smaller Q3 loss, stronger gross margin, and continued medical adoption, while reaffirming 2026 revenue guidance and saying it expects to reach or approach profitability in Q4 2026.· November 13, 2026
- Revenue was $2.2 million, down 5.9% year over year, as lower dental sales were partly offset by medical growth and higher dental repair income.
- Gross margin improved to 72.3% from 69.5%, and operating expense fell 15.3% to $2.4 million.
- Net loss narrowed to $748,000, or $0.01 per share, versus $1.2 million a year ago.
- Management reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million and said it expects to approach or achieve profitability in Q4 2026.
- The company said it ended the quarter debt-free, with $1.3 million in cash and $3.5 million in working capital.
Third-quarter revenue was $2.2 million, down from $2.4 million a year ago, a decline of $140,000 or 5.9%. Gross profit was $1.6 million, with gross margin improving to 72.3% from 69.5% last year. Operating expense decreased 15.3% to $2.4 million, operating loss improved to $746,000 from $1.1 million, and net loss narrowed to $748,000, or $0.01 per share, from $1.2 million a year ago. As of September 30, cash and cash equivalents were $1.3 million, working capital was $3.5 million, and the company had no outstanding debt. Management reaffirmed full-year 2026 revenue outlook of $9.8 million to $10.2 million and said it expects to approach or achieve profitability in Q4 2026; it also said quarterly revenue of about $2.6 million to $2.7 million may be near the threshold for meaningful bottom-line leverage.
Eric Hines framed the quarter as evidence of continued execution, cost discipline, and improving operating leverage. He emphasized that the company has added more than $400,000 in annual savings, converted director loans to equity, and is now debt-free, while also highlighting commercial traction in medical with Rothman Orthopaedics and Pain and Spine Specialists. His tone was confident and increasingly optimistic, repeatedly stressing that Milestone is approaching an inflection point and that Q4 2026 could be profitable.
Keisha Harcum focused on the quarter’s financial mechanics: revenue of $2.2 million, gross profit of $1.6 million, gross margin of 72.3%, operating expense of $2.4 million, operating loss of $746,000, and net loss of $748,000. She said lower product costs drove the higher margin, while lower salary, stock compensation, professional fees, and contract-related expenses helped reduce operating costs. She also noted the balance sheet ended with $1.3 million in cash, $3.5 million in working capital, and no debt.
Analysts pressed on gross margin sustainability, seasonality, the pace of international approvals, and whether medical sales are becoming recurring versus one-time equipment sales. Management said gross margin should settle back into the 69% to 70% range, that Q4 is generally a strong season, and that Turkey has now been approved while Mexico and India are expected in Q1 and Japan is being deferred for now. On the medical side, Eric Hines said about 85% of current medical revenue is still new sales, with recurring revenue likely to become more meaningful in mid-Q1 and Q2 next year after a four-to-six-month lag for training, usage, and reimbursement.
The call highlighted improving margins, lower costs, and a clear path to operating leverage, with management saying incremental revenue should now fall more directly to the bottom line. Management also pointed to expanding medical adoption, over 500 U.S. medical leads, and early traction with major healthcare systems as signs that CompuFlo could shift toward recurring disposable revenue.
Revenue still declined year over year, and management acknowledged that current medical sales are mostly new placements rather than recurring disposable revenue. Gross margin is expected to normalize lower than the quarter’s 72.3%, and management said recurring revenue may not become a major contributor until mid-Q1 or Q2 next year, leaving near-term execution dependent on continued new placements and adoption.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.9%
- Shares Outstanding
- 90.61M
- Float Shares
- 76.04M
of shares held by institutions
31 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.35M | ▼ 6.38K |
| Vanguard Capital Management LLC | 2.16M | ▲ 86.69K |
| Geode Capital Management, LLC | 654.45K | ▲ 10.84K |
| Vanguard Fiduciary Trust Co | 464.45K | 0 |
| State Street Corp | 264.88K | 0 |
| Northern Trust Corp | 133.07K | ▲ 20.45K |
| Lpl Financial LLC | 124.94K | 0 |
| Mariner, LLC | 121.75K | 0 |
| World Investment Advisors | 104.00K | 0 |
| Bridgeway Capital Management, LLC | 99.50K | 0 |
| Empowered Funds, LLC | 97.76K | ▲ 97.76K |
| Blackrock, Inc. | 65.45K | 0 |
Held by 20 ETFs
Biggest fund positions in MLSS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 25 | Harcum Kisha M | other | 0 |
| Oct 22, 25 | BP4 S.r.l. | sell | 14,427 |
| Oct 23, 25 | BP4 S.r.l. | sell | 80,000 |
| Oct 24, 25 | BP4 S.r.l. | sell | 100,000 |
| Oct 20, 25 | BP4 S.r.l. | sell | 24,034 |
| Oct 21, 25 | BP4 S.r.l. | sell | 40,000 |
| Oct 10, 25 | BP4 S.r.l. | sell | 10,158 |
| Oct 13, 25 | BP4 S.r.l. | sell | 10,000 |
| Oct 14, 25 | BP4 S.r.l. | sell | 30,000 |
| Oct 7, 25 | BP4 S.r.l. | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MLSS coverage
Recent articles, reports, and earnings notes.
No research on MLSS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLSS report →Milestone Scientific Inc. (MLSS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Milestone Scientific Reports Financial Results for Third Quarter 2026
globenewswire.com · Nov 13
CORRECTION: Milestone Scientific Schedules Third Quarter 2026 Financial Results Conference Call
globenewswire.com · Nov 11
Milestone Scientific Schedules Third Quarter 2026 Financial Results Conference Call
globenewswire.com · Nov 11
Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures
globenewswire.com · Oct 29
Critical Survey: TerrAscend (OTCMKTS:TSNDF) versus Milestone Scientific (NYSE:MLSS)
defenseworld.net · Oct 12
Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business
globenewswire.com · Sep 29
Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor
globenewswire.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.